Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Harbin Pharmaceutical Group Co - Stock

Harbin Pharmaceutical Group Co Stock

600664.SS
CNE0000009T3

Price

2.68
Today +/-
+0
Today %
+0 %
P

Harbin Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Harbin Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Harbin Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Harbin Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Harbin Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Harbin Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Harbin Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Harbin Pharmaceutical Group Co’s growth potential.

Harbin Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateHarbin Pharmaceutical Group Co RevenueHarbin Pharmaceutical Group Co EBITHarbin Pharmaceutical Group Co Net Income
2026e20.89 B undefined0 undefined840.34 M undefined
2025e18.76 B undefined0 undefined636.62 M undefined
2024e17.06 B undefined0 undefined483.83 M undefined
202315.46 B undefined683.68 M undefined395.26 M undefined
202213.81 B undefined600.14 M undefined464.36 M undefined
202112.8 B undefined520.13 M undefined371.08 M undefined
202010.79 B undefined-875 M undefined-1.08 B undefined
201911.83 B undefined188 M undefined56 M undefined
201810.81 B undefined512 M undefined346 M undefined
201712.02 B undefined545 M undefined407 M undefined
201614.13 B undefined937 M undefined788 M undefined
201515.86 B undefined738 M undefined580 M undefined
201416.51 B undefined344 M undefined247 M undefined
201318.09 B undefined257 M undefined169 M undefined
201217.66 B undefined892 M undefined500 M undefined
201117.46 B undefined1.1 B undefined889 M undefined
201012.54 B undefined1.17 B undefined1.13 B undefined
200910.68 B undefined1.01 B undefined933 M undefined
20089.7 B undefined914 M undefined862 M undefined
20078.29 B undefined569 M undefined592 M undefined
20069.27 B undefined734 M undefined467 M undefined
20058.49 B undefined765 M undefined456 M undefined
20047.18 B undefined383 M undefined263 M undefined

Harbin Pharmaceutical Group Co Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
1.762.042.252.272.934.496.445.376.526.937.188.499.278.299.710.6812.5417.4617.6618.0916.5115.8614.1312.0210.8111.8310.7912.813.8115.4617.0618.7620.89
-16.0110.710.8428.6853.4043.61-16.7021.376.353.5518.379.13-10.5516.9510.1317.4039.301.162.43-8.75-3.96-10.90-14.93-10.029.35-8.7718.677.8611.9410.379.9711.37
26.6126.0325.1625.5224.1736.8849.8441.3736.4239.8236.6335.8933.9032.2431.4031.3429.2429.2131.7229.2727.0324.4226.2025.8926.7823.7220.9123.3024.4126.02---
0.470.530.570.580.711.663.212.222.372.762.633.053.142.673.043.353.675.15.65.34.463.873.73.112.92.812.262.983.374.02000
0.220.240.230.230.210.250.370.450.460.510.380.770.730.570.911.011.171.10.890.260.340.740.940.550.510.19-0.880.520.60.68000
12.4811.5910.3810.217.285.595.748.297.007.395.349.017.926.869.439.459.336.325.051.422.084.656.634.534.731.59-8.114.064.354.42---
0.10.110.110.120.10.140.220.280.30.330.260.460.470.590.860.931.130.890.50.170.250.580.790.410.350.06-1.080.370.460.40.480.640.84
-7.92-11.01-19.0141.8456.8330.286.349.60-20.5473.382.4126.7745.618.2421.11-21.33-43.76-66.2046.15134.8235.86-48.35-14.99-83.82-2,025.00-134.4225.07-14.8722.2831.6832.08
1.481.481.482.082.082.441.782.12.12.12.12.12.12.12.12.12.12.12.492.492.492.492.542.552.552.512.512.472.582.47000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Harbin Pharmaceutical Group Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Harbin Pharmaceutical Group Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Harbin Pharmaceutical Group Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Harbin Pharmaceutical Group Co's financial health and stability.

Assets

Harbin Pharmaceutical Group Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Harbin Pharmaceutical Group Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Harbin Pharmaceutical Group Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Harbin Pharmaceutical Group Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0000000000000000000000000
0000000000000000000000000
0000000000000000000000000
-149-946-2,103-724-1,306-1,362-1,242-1,187-1,263-1,044-976-824-1,029-3,063-3,822-4,200-4,134-2,775-2,633-2,466-2,427-2,606-2,647-2,646-2,978
0000000000000000000000000
0000000000000000000000000
-583-325-736-525-673-724-796-696-766-538-774-936-915-1,280-1,704-1,271-1,374-1,114-1,104-1,092-827-614-610-711-728
0.220.430.540.490.380.30.150.760.740.650.581.851.15-0.10.560.141.141.662.780.150.69-0.28-0.73-0.160.62
-100-184-582-552-391-473-428-443-326-175-143-223-299-361-275-369-375-290-107-102-114-39-118-76-89
-69-175-563-634-390-469-425-265-393-378-457165-52-290-309-297-384-284-76-68-804-1,374-1019172
31918-82042178-67-203-31438924771-3372-963134-690-1,33517168161
0000000000000000000000000
0.03-0.17-0.08-0.0700.070.240.04-0.140.54-0.56-0.81-00.31-0.18-0.14-0.010.03-0.010.11-0.010.411.090.680.13
000970600000000000000000000
-0.090.06-0.150.79-0.07-00.15-0.04-0.120.49-0.67-1.6-0.59-0.51-0.19-0.15-0.15-1.890.11-1.21-1.360.291.060.390.17
-97232-3900151814568-1000017000211261-114-9-228101
-220-34-115-79-86-108-87-33-58-96-795-589-812-25-8-144-1,924-83-1,346-1,350-10-14-61-54
1.022.023.212.382.292.222.063.12.9931.784.033.63.346.155.317.245.039.332.582.481.562.763.515.2
120.7246.8-40.8-65.3-7.6-170.9-279.6314.2411.8475.2435.51,628.3853.5-465.2282-228.3760.71,369.22,670.547.2578.6-323.9-846.4-239.13532.45
0000000000000000000000000

Harbin Pharmaceutical Group Co stock margins

The Harbin Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harbin Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harbin Pharmaceutical Group Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Harbin Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Harbin Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Harbin Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Harbin Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Harbin Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Harbin Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Harbin Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Harbin Pharmaceutical Group Co Margin History

Harbin Pharmaceutical Group Co Gross marginHarbin Pharmaceutical Group Co Profit marginHarbin Pharmaceutical Group Co EBIT marginHarbin Pharmaceutical Group Co Profit margin
2026e26.02 %0 %4.02 %
2025e26.02 %0 %3.39 %
2024e26.02 %0 %2.84 %
202326.02 %4.42 %2.56 %
202224.41 %4.35 %3.36 %
202123.31 %4.06 %2.9 %
202020.91 %-8.11 %-9.99 %
201923.72 %1.59 %0.47 %
201826.78 %4.73 %3.2 %
201725.89 %4.53 %3.39 %
201626.2 %6.63 %5.58 %
201524.42 %4.65 %3.66 %
201427.03 %2.08 %1.5 %
201329.27 %1.42 %0.93 %
201231.72 %5.05 %2.83 %
201129.21 %6.32 %5.09 %
201029.24 %9.33 %9.01 %
200931.34 %9.45 %8.74 %
200831.4 %9.43 %8.89 %
200732.24 %6.86 %7.14 %
200633.9 %7.92 %5.04 %
200535.89 %9.01 %5.37 %
200436.63 %5.34 %3.67 %

Harbin Pharmaceutical Group Co Stock Sales Revenue, EBIT, Earnings per Share

The Harbin Pharmaceutical Group Co earnings per share therefore indicates how much revenue Harbin Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Harbin Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Harbin Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Harbin Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Harbin Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Harbin Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateHarbin Pharmaceutical Group Co Sales per ShareHarbin Pharmaceutical Group Co EBIT per shareHarbin Pharmaceutical Group Co Earnings per Share
2026e8.29 undefined0 undefined0.33 undefined
2025e7.44 undefined0 undefined0.25 undefined
2024e6.77 undefined0 undefined0.19 undefined
20236.26 undefined0.28 undefined0.16 undefined
20225.35 undefined0.23 undefined0.18 undefined
20215.17 undefined0.21 undefined0.15 undefined
20204.3 undefined-0.35 undefined-0.43 undefined
20194.72 undefined0.07 undefined0.02 undefined
20184.25 undefined0.2 undefined0.14 undefined
20174.71 undefined0.21 undefined0.16 undefined
20165.56 undefined0.37 undefined0.31 undefined
20156.36 undefined0.3 undefined0.23 undefined
20146.62 undefined0.14 undefined0.1 undefined
20137.26 undefined0.1 undefined0.07 undefined
20127.09 undefined0.36 undefined0.2 undefined
20118.32 undefined0.53 undefined0.42 undefined
20105.97 undefined0.56 undefined0.54 undefined
20095.09 undefined0.48 undefined0.44 undefined
20084.62 undefined0.44 undefined0.41 undefined
20073.95 undefined0.27 undefined0.28 undefined
20064.42 undefined0.35 undefined0.22 undefined
20054.05 undefined0.36 undefined0.22 undefined
20043.42 undefined0.18 undefined0.13 undefined

Harbin Pharmaceutical Group Co business model

Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.com.

Harbin Pharmaceutical Group Co valuation based on historical P/E ratio, EBIT, and P/S ratio.

Harbin Pharmaceutical Group Co shares outstanding

The number of shares was Harbin Pharmaceutical Group Co in 2023 — This indicates how many shares 2.47 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Harbin Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Harbin Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Harbin Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Harbin Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Harbin Pharmaceutical Group Co Stock splits

In Harbin Pharmaceutical Group Co's history, there have been no stock splits.

Harbin Pharmaceutical Group Co Stock Dividend

In 2023, Harbin Pharmaceutical Group Co paid a dividend amounting to 0 CNY. Dividend means that Harbin Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Harbin Pharmaceutical Group Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Harbin Pharmaceutical Group Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Harbin Pharmaceutical Group Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Harbin Pharmaceutical Group Co Dividend History

DateHarbin Pharmaceutical Group Co Dividend
20180.5 undefined
20170.5 undefined
20150.77 undefined
20140.05 undefined
20110.34 undefined
20100.29 undefined
20090.35 undefined
20080.06 undefined
20040.06 undefined

Harbin Pharmaceutical Group Co Stock Payout Ratio

In 2023, Harbin Pharmaceutical Group Co had a payout ratio of 338.11%. The payout ratio indicates the percentage of the company's profits that Harbin Pharmaceutical Group Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Harbin Pharmaceutical Group Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Harbin Pharmaceutical Group Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Harbin Pharmaceutical Group Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Harbin Pharmaceutical Group Co Payout Ratio History

DateHarbin Pharmaceutical Group Co Payout ratio
2026e338.51 %
2025e338.2 %
2024e339.21 %
2023338.11 %
2022337.28 %
2021342.24 %
2020334.81 %
2019334.78 %
2018357.14 %
2017312.5 %
2016334.69 %
2015334.43 %
201450.8 %
2013334.69 %
2012334.69 %
201181.71 %
201053.69 %
200979.34 %
200814.44 %
2007334.69 %
2006334.69 %
2005334.69 %
200445.54 %
Unfortunately, there are currently no price targets and forecasts available for Harbin Pharmaceutical Group Co.

Harbin Pharmaceutical Group Co Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20150.02 0.09  (495.55 %)2015 Q2
12/31/20140.02 -0.03  (-232.06 %)2014 Q4
9/30/2014-0.06 0  (103.34 %)2014 Q3
6/30/2014-0.02 0.06  (364.12 %)2014 Q2
12/31/20130.11 -0.04  (-135.35 %)2013 Q4
9/30/20130.24 0.03  (-86.26 %)2013 Q3
6/30/20130.08 -0.02  (-120.74 %)2013 Q2
9/30/20110.12 0.1  (-18.7 %)2011 Q3
6/30/20110.16 0.12  (-23.92 %)2011 Q2
12/31/20100.13 0.14  (6.57 %)2010 Q4
1
2

Harbin Pharmaceutical Group Co Stock Shareholders

%
Name
Stocks
Change
Date
46.53 % Harbin Pharmaceutical Group Holding Co., Ltd.1,173,237,02309/30/2023
2.21 % China Securities Investor Protection Fund Corporation55,725,12509/30/2023
1.02 % Fullgoal Fund Management Co., Ltd.25,723,440-28,8009/30/2023
0.95 % Zhejiang Zhecai Capital Management Co., Ltd.23,883,41809/30/2023
0.79 % Sun (Kun)20,000,000-1,000,0009/30/2023
0.64 % Shanghai Urban Construction Property Development Co., Ltd.16,055,00009/30/2023
0.63 % Lian (Yong)15,844,800102,7889/30/2023
0.56 % Xia (Chongyang)14,200,0003,900,0009/30/2023
0.21 % The Vanguard Group, Inc.5,338,4151,756,3003/31/2024
0.11 % China Merchants Fund Management Co. Ltd.2,767,7002,767,7006/30/2023
1
2
3
4
...
5

Harbin Pharmaceutical Group Co stock: Frequently Asked Questions

What is the P/E ratio of Harbin Pharmaceutical Group Co 2024?

The Harbin Pharmaceutical Group Co P/E ratio is 13.68.

What is the P/S ratio of Harbin Pharmaceutical Group Co 2024?

The Harbin Pharmaceutical Group Co P/S ratio is 0.39.

What is the AlleAktien quality score of Harbin Pharmaceutical Group Co?

The AlleAktien quality score for Harbin Pharmaceutical Group Co is 4/10.

What is the revenue of Harbin Pharmaceutical Group Co 2024?

The expected Harbin Pharmaceutical Group Co revenue is 17.06 B CNY.

How high is the profit of Harbin Pharmaceutical Group Co 2024?

The expected Harbin Pharmaceutical Group Co profit is 483.83 M CNY.

What is the business model of Harbin Pharmaceutical Group Co

No history available for Harbin Pharmaceutical Group Co.

What is the Harbin Pharmaceutical Group Co dividend?

Harbin Pharmaceutical Group Co pays a dividend of 0 CNY distributed over payouts per year.

How often does Harbin Pharmaceutical Group Co pay dividends?

The dividend cannot currently be calculated for Harbin Pharmaceutical Group Co or the company does not pay out a dividend.

What is the Harbin Pharmaceutical Group Co ISIN?

The ISIN of Harbin Pharmaceutical Group Co is CNE0000009T3.

What is the Harbin Pharmaceutical Group Co ticker?

The ticker of Harbin Pharmaceutical Group Co is 600664.SS.

How much dividend does Harbin Pharmaceutical Group Co pay?

Over the past 12 months, Harbin Pharmaceutical Group Co paid a dividend of 0.5 CNY . This corresponds to a dividend yield of about 18.66 %. For the coming 12 months, Harbin Pharmaceutical Group Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Harbin Pharmaceutical Group Co?

The current dividend yield of Harbin Pharmaceutical Group Co is 18.66 %.

When does Harbin Pharmaceutical Group Co pay dividends?

Harbin Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of September, December, May, June.

How secure is the dividend of Harbin Pharmaceutical Group Co?

Harbin Pharmaceutical Group Co paid dividends every year for the past 3 years.

What is the dividend of Harbin Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Harbin Pharmaceutical Group Co located?

Harbin Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Harbin Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Harbin Pharmaceutical Group Co from 5/4/2018 amounting to 0.5 CNY, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.

When did Harbin Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 5/4/2018.

What was the dividend of Harbin Pharmaceutical Group Co in the year 2023?

In the year 2023, Harbin Pharmaceutical Group Co distributed 0 CNY as dividends.

In which currency does Harbin Pharmaceutical Group Co pay out the dividend?

The dividends of Harbin Pharmaceutical Group Co are distributed in CNY.

Other fundamentals and analyses of Harbin Pharmaceutical Group Co in the deep dive.

Our stock analysis for Harbin Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harbin Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.